Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Skye Bioscience

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab.

Benzinga · Oct 6, 2025

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga · Sep 19, 2025

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

Benzinga · Sep 5, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Is This Penny Stock’s 525% Upside Potential an Attainable Goal?

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

Barchart · Feb 26, 2025

2 Growth Stocks With 20% to 40% Upside in 2024

Both of these companies’ innovative products present excellent long-term opportunities for investors seeking growth in the stock market.

Barchart · Mar 28, 2024

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (&ld

Benzinga · Sep 20, 2022

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial mat

Benzinga · Jul 21, 2022

Read news from The Economist, FT, and more,
with one subscription

Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details

Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc.

Benzinga · May 12, 2022

Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma

Skye Bioscience, Inc. (OTCQB: SKYE) has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization in Asia-Pacific, for its upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma.

Benzinga · Mar 3, 2022

Coverage From

People

William Blair

55 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.